Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749284 | 0.93 | PRCP (0.49) | PRCPMAPTSMN1; SMN2POLBGRM5 | |
| SCHEMBL14749314 | 0.92 | PRCP (0.58) | PRCPGRM5ALDH1A1 | |
| SCHEMBL12183916 | 0.92 | PRCP (0.58) | PRCPGRM5ALDH1A1 | |
| SCHEMBL14749302 | 0.91 | PRCP (0.48) | PRCPMAPTSMN1; SMN2POLB | |
| SCHEMBL14737070 | 0.90 | PRCP (0.54) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL14752639 | 0.87 | PRCP (0.52) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL12183915 | 0.83 | PRCP (0.43) | PRCPMAPTSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL12184583 | 0.83 | PRCP (0.52) | PRCP | |
| SCHEMBL14749421 | 0.83 | PRCP (0.55) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL14749294 | 0.82 | PRCP (0.47) | PRCPMAPTSMN1; SMN2POLBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| WO-2011146354-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885MAPT 3765/4885SMN1; SMN2 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.